mProX™ Human P2RY2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ATP and UTP, which are P2RY2's natural agonists, stimulate P2RY2's activity. P2RY2 was activated, and like other typical G protein receptors, the intracellular C-terminal of P2RY2 interacted with the G-protein, causing the intracellular C-terminal of P2RY2 to be phosphorylated and leading to a number of physiological reactions. Initiating early inflammatory responses and mediating later regenerative responses necessary for wound healing, cell migration, and liver regeneration are essential functions of P2RY2. Since P2RY2 is widely distributed throughout the body's tissues and has pathophysiological functions in a variety of functional areas, including immunological disorders, cancer progression, and lung diseases. It is a potential therapeutic target for the condition known as dry eye. The first P2RY2 agonist is a medication called diquafosol tetrasodium, which is used to treat dry eye condition. Many agonists that target P2RY2 are currently being developed to treat various disorders. The customized P2RY2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.